Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

358 Features
BIPOLAR DISORDER: a new holistic approach

30 Jul 07

BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects
Olwen Glynn Owen

Wyeth Reports Earnings Results for the 2007 Second Quarter and First Half

25 Jul 07

Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007 second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to $5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7% for the 2007 second quarter and 8% for the 2007 first half.
Douglas Petkus

Market Leading Pharmaceutical Recruitment Consultancy Barrington James Limited is happy to announce the appointment of Tony Kelleher as its Sales Manager

02 Jul 07

Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
Dan Barrington

Erbitux moves to front-line in attack against both metastatic head and neck and colorectal cancers

11 Jun 07

The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
Olwen Glynn Owen

Sponsor a CEO

11 Jun 07

Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra).
Editor

CRYSTAL trial reveals benefits of first-line cetuximab in mCRC

08 Jun 07

Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
Olwen Glynn Owen

Lhasa Acts in Support of Science Education in Africa

05 Jun 07

In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference.
Lhasa Limited

BENEFiT study shows Tracleer (bosentan) improves haemodynamics in CTEPH patients refused surgery

04 Jun 07

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this year’s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition.
Olwen Glynn Owen

So you want to contract staff… what do you need to consider?

23 May 07

In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market.
Paula Mumby

What’s Up (Junior) Doc?

22 May 07

With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe that’s what the MTAS (the Medical Training Application Service - an online application system designed to allow juniors to apply centrally for training rotations) was meant to achieve. However, it had been prone to crashing, and many junior doctors claimed that it was
Paul Hartigan

The Newspaper Cemetery

14 May 07

Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play it’s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket.
Naseem Javed

Questioning whether age discrimination affects pharma recruitment

10 May 07

Its hard gaining entry into the pharmaceutical industry, but is it harder if you are thirty? I’m a graduate, so I can get in like a graduate, can’t I?
Toni Gardner

Europeans in the ‘twilight zone’ of type 2 diabetes care are living under a false sense of security and set to suffer avoidable long-term consequences

23 Apr 07

The results of an in-depth survey of over 750 patients across Europe launched today points to a crisis in the management of the rising numbers of people living in the ‘twilight zone’ of type 2 diabetes care.
Gaja Pellegrini-Bettoli

Wyeth’s Winning Ways: Big Pharma Bounces Back

20 Apr 07

After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry.
Paul Hartigan

A Gala Tribute to Global Copycats

03 Apr 07

Over the decade, the art of copying and stealing other people's content and ideas has settled comfortably in the mainstream across the globe. What formerly would constitute an act of piracy is now a commonplace, everyday occurrence. Isn't it time to give these 'borrowers' a tribute, host a gala dinner and hand out awards?
Naseem Javed

Global Image Re-Positioning 2007

30 Jan 07

Suddenly, there is a new global tidal wave of change all over the Asian region, the obvious signs are people on the move, new developments and properties popping up all over the region and a nouvo-consumerism is appearing at every corner, customers are buying shiny and wonderful things with beautiful packaging and companies are addressing their hunger with massive blitzes. ...
Naseem Javed

Reducing Risks of Infusion Related Reactions in Targeted Cancer Therapy

30 Jan 07

Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk.
Olwen Glynn Owen

The iPhones, iPains & iProblems

16 Jan 07

The Appendage of the letter "i" to a word as an aim to create an icon is silly…
Naseem Javed

Eltrombopag (Promacta) offers hope of an effective oral treatment for bleeding due to thrombocytopenia

03 Jan 07

Thrombocytopenia, the bleeding disorder caused by a deficiency of platelets, has no easy-to-administer or satisfactory treatment at present. However, eltrombopag (Promacta) a new oral drug in development by GlaxoSmithKline (GSK) has progressed to phase III
Olwen Glynn Owen

Pharma turns to reformulation to maximize ROI

15 Dec 06

With drug pipelines yielding fewer blockbusters and profits from branded drugs being increasingly eroded by generic incursion, pharmaceutical companies are looking to maximize the return on investment of their drugs that do make it to market. Consequently, reformulation has become a common defense by drug makers to prolong the lifecycle of their top sellers.
Datamonitor

AstraZeneca has announced that it will launch a generic version of its own heart drug Toprol XL.

24 Nov 06

AstraZeneca's third biggest-selling drug, Toprol XL, has come up against generic competition sooner than anticipated after losing its protection against copycat launches. AstraZeneca has responded by reaching an agreement with US generic firm Par Pharmaceutical to distribute and supply a 25mg generic version of Toprol XL, a strategy that could be used with its other drugs facing patent expiry.
Datamonitor

The PharmiWeb.com e:HR Awards 2006

25 Oct 06

Recognizing excellence in the application of an e-business approach in pharma and biotech HR in Europe.
Mike Wood

Has the current approach to pharmaceutical sales passed its expiry date?

17 Oct 06

It’s another Monday practice meeting, the usual drug representative has been roped in to provide lunch and is cooling her heels waiting for the team to finish morning surgery. The usual non-descript pile of sandwiches from the local bakery is stacked on the table and the registrar who has finished early has already picked the best sandwiches...
Ian Mckenzie - PharmiWeb.com Field Reporter

Age is no longer a factor

02 Oct 06

From October 1st 2006 the Employment Equality (Age) Regulations 2006 - is coming in to force, making it illegal in the UK to recruit or select candidates based on their age and to discriminate based on age whilst in employment rather than based on skills and competencies. This will apply to discrimination againt young and old, and it WILL dramatically affect recruitment and employment in the UK.
Mike Wood

DPP-4 inhibitors Galvus and Januvia will be the first oral drugs tackling Type 2 diabetes via the incretin response: how do they compare?

27 Sep 06

A new DPP-4 inhibitor class of oral anti-diabetic medicines, working by the novel mechanism of incretin enhancement, is poised to revolutionise the management of Type 2 diabetes. Data presented at a recent European Association for the Study of Diabetes meeting suggest they will help fill the unmet need for effective anti-diabetic drugs without unacceptable side effects. Numerous agents are in development with two, Galvus (vildagliptin, Novartis) and Januvia (sitagliptin, Merck) awaiting approval
Olwen Glynn Owen - PharmiWeb Field Reporter

International Conference on Silicone Elastomes Highlights Future Growth

25 Sep 06

Rapra Technology’s First International Conference on Silicone Elastomers took place in Frankfurt on 19-20 September attracting over 120 delegates from as far away as Australia, Brazil, Russia and the US. Presentations covered silicone elastomer materials, liquid silicone rubber, the processing of silicone elastomers, additives and finishing for silicone elastomers. Delegates praised the breadth of the programme content and the practical nature of many of the papers.
Sharon Garrington

GSK: given green light to restrict Greek drug supply

20 Sep 06

The Hellenic Competition Committee has issued GSK with a favorable decision, indicating that it can restrict the supply of pharmaceuticals to wholesalers to prevent parallel importation of these drugs, without breaking competition laws. This is an important step for legally restricting parallel importation from one of Europe's biggest parallel trade markets, as Datamonitor's Dr Mark Belsey discovers…
Datamonitor

Meet the Country

20 Sep 06

Running clinical trials and recruiting experienced clinical personnel in the UK has certainly challenged many senior managers and recruiters over the past year. At a recent UK conference, both the Association of the British Pharmaceutical Industry (ABPI) and a UK pharmaceutical website were quoted as stating that there continues to be a skills shortage across all disciplines; a lack of long-term educational investment and less development of the existing talent pool were cited as the main reaso
Iain Jessup

PHASE IV CLINICAL TRIALS: Post Marketing Studies

19 Sep 06

Strategic Research Institute’s Phase IV Clinical Trials (PCT) conference features a fully packed informational two day event organized into a series of discussions focusing on the major Phase IV and Patient Recruitment/ Retention issues of today.
Amy Yueh

Pay for Performance: Strategies for Achieving Value and Improving Health Outcomes

19 Sep 06

GAIN VALUABLE INSIGHT INTO: • How CMS’ movement toward P4P will Impact Healthcare and Payors Nationwide • Large Employer HR Strategy: How Aligning Incentives and Creating a Health • Information Exchange will Reduce your Healthcare Spend • Health Plans: How Data, Transparency and Consumers will Affect your P4P Initiatives
Seth Fritts

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.